Literature DB >> 19336373

Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants.

Joakim Janér1, Sture Andersson, Eero Kajantie, Patrik Lassus.   

Abstract

INTRODUCTION: Endostatin is an antiangiogenic growth factor. Together with proangiogenic growth factors it acts to shape the developing vasculature. Dysregulation of angiogenesis is a component in the pathogenesis of bronchopulmonary dysplasia.
OBJECTIVE: Our goal was to study whether the concentration of circulating endostatin at birth is associated with the development of bronchopulmonary dysplasia in very low birth weight infants. PATIENTS AND METHODS: Endostatin concentration was measured in cord plasma from 92 very low birth weight infants (gestational age < 32 weeks; birth weight < 1500 g) and 48 healthy term infants (gestational age > 37 weeks; birth weight > 2500 g).
RESULTS: Endostatin concentration in very low birth weight infants was lower than in healthy term infants. Within the very low birth weight group no correlation existed between endostatin concentration and gestational age or relative birth weight. Very low birth weight infants who subsequently developed bronchopulmonary dysplasia had higher cord endostatin than those who did not. Higher endostatin concentration was associated with higher odds for bronchopulmonary dysplasia. Adjusted for gestational age, the odds for bronchopulmonary dysplasia were higher.
CONCLUSIONS: Circulating endostatin in term infants was higher than in very low birth weight infants, suggesting a temporal pattern for fetal endostatin concentration. In very low birth weight infants a high concentration of circulating endostatin at birth is associated with the subsequent development of bronchopulmonary dysplasia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336373     DOI: 10.1542/peds.2008-1339

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia.

Authors:  Sun K Kim; Roberto Romero; Zeynep A Savasan; Yi Xu; Zhong Dong; Deug-Chan Lee; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  Am J Reprod Immunol       Date:  2012-12-24       Impact factor: 3.886

Review 2.  The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series).

Authors:  Steven H Abman; Christopher Baker; Jason Gien; Peter Mourani; Csaba Galambos
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 3.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

4.  Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia.

Authors:  Christopher D Baker; Vivek Balasubramaniam; Peter M Mourani; Marci K Sontag; Claudine P Black; Sharon L Ryan; Steven H Abman
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

Review 5.  Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia.

Authors:  Charitharth Vivek Lal; Namasivayam Ambalavanan
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

Review 6.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

Authors:  Peter M Mourani; Steven H Abman
Journal:  Clin Perinatol       Date:  2015-09-26       Impact factor: 3.430

Review 7.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

8.  Pulmonary Function and Systolic Blood Pressure in Very Low Birth Weight Infants at 34 - 36 Weeks of Corrected Age.

Authors:  Ladawna L Gievers; Randall D Jenkins; Amy Laird; Marissa C Macedo; Diane Schilling; Cindy T McEvoy
Journal:  Res Rep Neonatol       Date:  2019-09-13

Review 9.  Addressing the challenges of phenotyping pediatric pulmonary vascular disease.

Authors:  Kara N Goss; Allen D Everett; Peter M Mourani; Christopher D Baker; Steven H Abman
Journal:  Pulm Circ       Date:  2017-01-01       Impact factor: 3.017

Review 10.  Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant.

Authors:  Lidys Rivera; Roopa Siddaiah; Christiana Oji-Mmuo; Gabriela R Silveyra; Patricia Silveyra
Journal:  Front Pediatr       Date:  2016-03-31       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.